Proteomic patterns analysis with multivariate calculations as a promising tool for prompt differentiation of early stage lung tissue with cancer and unchanged tissue material

Diagnostic Pathology

Volumn 6, Issue 1, 2011, Pages

  Waloszczyk, Piotr ^a   Janus, Tomasz ^a   Alchimowicz, Jacek ^b   Grodzki, Tomasz ^b   Borowiak, Krzysztof ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b Sokolowski Specialist Hospital Szczecin Zdunowo   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; EARLY DIAGNOSIS; HUMAN; LUNG TUMOR; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; PEPTIDE MAPPING; PRINCIPAL COMPONENT ANALYSIS; PROTEIN MICROARRAY; PROTEOMICS;

EARLY DETECTION OF CANCER; HUMANS; LUNG NEOPLASMS; NEOPLASM PROTEINS; PEPTIDE MAPPING; PRINCIPAL COMPONENT ANALYSIS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 79953104928     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-6-22     Document Type: Article

References (21)

1. Palmblad M, Tiss A, Cramer R. Mass spectrometry in clinical proteomics - from the present to the future. Proteomics Clin Appl 2009, 3:6-17. 10.1002/prca.200800090, 21136932.
2. Munro NP, Cairns DA, Clarke P, Rogers M, Stanley AJ, Barrett JH, Harnden P, Thompson D, Eardley I, Banks RE, Knowles MA. Urinary biomarker profiling in transitional cell carcinoma. Int J Cancer 2006, 119:2642-2650. 10.1002/ijc.22238, 16991122.
3. Coombes KR, Morris JS, Hu J, Edmonson SR, Baggerly KA. Serum proteomics profiling - a young technology begins to mature. Nature Biotechnol 2005, 23:291-292.
4. Check E. Proteomics and cancer: running before we can walk. Nature 2004, 429:496-497. 10.1038/429496a, 15175721.
5. Zhang X, Leung SM, Morris CR, Shigenaga MK. Evaluation of a novel, integrated approach using functionalized magnetic beads, bench-top MALDI-TOF-MS with prestructured sample supports, and pattern recognition software for profiling potential biomarkers in human plasma. J Biomol Technol 2004, 15:167-175.
6. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002, 48:1296-1304.
7. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359:572. 10.1016/S0140-6736(02)07746-2, 11867112.
8. Conrads TP, Zhou M, Petricoin EF, Liotta LA, Veenstra TD. Cancer diagnosis using proteomic patterns. Expert Rev Mol Diagn 2003, 3:411. 10.1586/14737159.3.4.411, 12877381.
9. Aebersold R, Goodlett DR. Mass spectrometry in proteomics. Chem Rev 2001, 101:269-295. 10.1021/cr990076h, 11712248.
10. Stoeckli M, Staab D, Schweitzer A. Compound and metabolite distribution measured by MALDI mass spectrometric imaging in whole-body tissue sections. Int J Mass Spectrom 2007, 260:195-202.
11. Andersson M, Groseclose MR, Deutch AY, Caprioli RM. Imaging mass spectrometry of proteins and peptides: 3 D volume reconstruction. Nat Methods 2008, 5:101-108. 10.1038/nmeth1145, 18165806.
12. Caldwell RL, Caprioli RM. Tissue profiling by mass spectrometry: A review of methodology and applications. Mol Cell Proteomics 2005, 4:394-401. 10.1074/mcp.R500006-MCP200, 15677390.
13. Chaurand P, Norris JL, Cornett DS, Mobley JA, Caprioli RM. New developments in profiling and imaging of proteins from tissue sections by MALDI mass spectrometry. J Proteome Res 2006, 5:2889-2900. 10.1021/pr060346u, 17081040.
14. Cornett DS, Reyzer ML, Chaurand P, Caprioli RM. MALDI imaging mass spectrometry: Molecular snapshots of biochemical systems. Na Methods 2007, 4:828-833.
15. Khatib-Shahidi S, Andersson M, Herman JL, Gillespie TA, Caprioli RM. Direct molecular analysis of whole-body animal tissue sections by imaging MALDI mass spectrometry. Anal Chem 2006, 78:6448-6456. 10.1021/ac060788p, 16970320.
16. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: The long and uncertain path to clinical utility. Nat Biotechnol 2006, 24:971-983. 10.1038/nbt1235, 16900146.
17. Duncan R, McConkey EH. How many proteins are there in a typical mammalian cell?. Clin Chem 1982, 28:749-755.
18. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 2004, 3:367-378. 10.1074/mcp.R400007-MCP200, 14990683.
19. Omenn GS. Strategies for plasma proteomic profiling of cancers. Proteomics 2006, 6:5662-5673. 10.1002/pmic.200600331, 16991194.
20. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: The long and uncertain path to clinical utility. Nat Biotechnol 2006, 24:971-983. 10.1038/nbt1235, 16900146.
21. Görg A, Weiss W, Dunn MJ. Current two-dimensional electrophoresis technology for proteomics. Proteomics 2004, 4:3665-3685.